Marinomed Biotech AG · VIE:MARI
Marinomed Biotech — Fact Sheet (November 2023)
12 slides from Marinomed Biotech's fact sheet, November 2023
Slide 1: Carragelose: Prophylaxis and therapy against allergic rhinitis
Carragelose Prophylaxis and therapy against allergic rhinitis November 2023
Slide 2: Disclaimer
Disclaimer These materials (the “Presentation”) have been provided to you by Marinomed Biotech AG together with its respective members, directors, officers, employees, advisers or agents (together “Marinomed”) in connection with a potential transaction relating to Marinomed’s asset Carragelose (the
Slide 3: Executive summary: Carragelose allergy products
Executive summary: Carragelose allergy products Two independent products for prophylaxis and therapy of allergic rhinitis Business model Market opportunity Carragelose Safety • Open for partnering in • Fast growing allergy • Sulfated polymer • Excellent safety profile classical license deal market (
Slide 4: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in the Vienna region 2006 2008 2016 2019 2021 2022 Foundation Launch of Carragelose Invention of IPO and Marinosolv Marinosolv deal and Deal with Marinosolv clinical validation Solv4U launch Procter & Gamble Therapeutic areas VI
Slide 5: Pipeline
Pipeline Including late-stage projects with low risk and high upside potential © Marinomed Biotech AG 5
Slide 6: Carragelose: protective layer against viruses and allergens
Carragelose® CCA2 market volume: Protective layer against viruses and allergens – multi-use potential US$ 36 bn3 Viral respiratory diseases Carragelose Eye care • Broadly-active against numerous • Carragelose has excellent respiratory viruses moisturizing and mucoadhesive properties • Clinically val
Slide 7: Carragelose mode of action and benefits
Carragelose mode of action and benefits Mode of action1 • Carragelose non-specifically covers the mucosal surface and prevents binding of virus/allergen to the mucosa, thereby reducing the immune response without being pharmacologically active • Newly synthesized virus particles released by already
Slide 8: Carragelose, Virus and Allergen Blocker
Carragelose, Virus and Allergen Blocker Safe and effective active ingredient to protect the mucosa from allergens • Carragelose is iota-carrageenan derived from red seaweed in pharmaceutical quality • Carragelose protects the nasal mucosa from contact with allergens; hyperosmolar Carragelose product
Slide 9: Allergic rhinitis nasal spray
Allergic rhinitis nasal spray Provides symptomatic relief in mild and moderate allergic rhinitis Product characteristics: • Regulatory status: medical device class I (EU), application for MDR (class IIa) transition period until latest May 2024 • Legal manufacturer: MoNo chem-pharm Produkte GmbH, Vie
Slide 10: Allergen blocking decongestant nasal spray
Allergen blocking decongestant nasal spray Provides symptomatic relief in both, allergic and infectious rhinitis Product characteristics: • Regulatory status: medical device class Is (EU, MDD), application for MDR (IIa) by end of 2023; valid CE mark under transition period until 2028 (MDD) • Legal m
Slide 11: Carragelose – clinical trials overview
Carragelose – clinical trials overview Trial Subjects Indication Published Supports claims Cardiff 35 Common cold yes yes Children’s trial 153 Common cold yes yes Adult’s trial 211 Common cold yes yes BI Trial 200 Common cold yes yes Lozenge trial 27 Sore throat yes yes Allergy trial 42 Allergic rhi
Slide 12: www.marinomed.com www.carragelose.com
www.marinomed.com www.carragelose.com Contact: [email protected]